Sagimet Biosciences Inc. Series A (SGMT) Live Share Price, Invest From India

Sagimet Biosciences Inc. Series A Stock Performance

as on June 19, 2026 at 2:16 pm IST

Day's Low
Day's High
$6.58
Day's Price Range
$6.86
$6.68
1.50%
Downside
2.69%
Upside
52 Week's Low
52 Week's High
$4.50
52-Week Price Range
$11.41
$6.68
32.63%
Downside
70.81%
Upside

Sagimet Biosciences Inc. Series A share price movements today

Previous Close: $6.53
Open: $6.71
Volume: 1.6M
Day's Low - High: $6.58 - $6.86
52 Week Low - High: $4.50 - $11.41

Sagimet Biosciences Inc. Series A Historical Returns

1 Month Return: + 2.14 %
3 Month Return: + 38.3 %
1 Year Return: -5.11 %
3 Year Return: 0 %
5 Year Return: 0 %

Sagimet Biosciences Inc. Series A Stock Fundamentals & Key Indicators

Check Sagimet Biosciences Inc. Series A market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$403.2M

EPS (TTM)

-1.2221

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

PEG Ratio

EBITDA

Revenue (TTM)

Profit Margin

0.00%

Return On Equity TTM

-36.04%

Sagimet Biosciences Inc. Series A vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Sagimet Biosciences Inc. Series A with its industry peers.

Company	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin %	Dividend Yield %
Sagimet Biosciences Inc. Series A	BUY	$403.2M	NA	NA	0.00%	NA
Alnylam Pharmaceuticals Inc.	BUY	$37.7B	57.21%	71.21	12.55%	NA
Vertex Pharmaceuticals Inc.	BUY	$116.5B	140.42%	27.22	35.51%	NA
Regeneron Pharmaceuticals Inc.	BUY	$63.7B	13.39%	14.85	29.65%	0.58%

Stock Returns calculator for Sagimet Biosciences Inc. Series A Stock including INR - Dollar returns

The Sagimet Biosciences Inc. Series A stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

Sagimet Biosciences Inc. Series A investment value today

Current value as on today

₹1,03,358

Returns

₹3,358

(+3.36%)

Returns from Sagimet Biosciences Inc. Series A Stock

-₹5,114 (-5.11%)

Dollar Impact

₹8,472 (+8.47%)

Analyst Recommendation on Sagimet Biosciences Inc. Series A Stock

Based on 11 analysts

BUY

90.91%

Buy

9.09%

Hold

0.00%

Sell

Based on 11 analysts, 90.91% of analysts recommend a 'BUY' rating for Sagimet Biosciences Inc. Series A. Average target price of $26.2

Sagimet Biosciences Inc. Series A Share Price Target

Get share price movements and forecasts by analysts on Sagimet Biosciences Inc. Series A.

What analysts predicted

74.5%UPSIDE

Target Price

$26.2

Current Price

$6.68

Analyzed by

11 Analysts

Target

$26.20

Sagimet Biosciences Inc. Series A target price $26.2, a slight upside of 74.5% compared to current price of $6.68. According to 11 analysts rating.

Indian Investors' Interest in Sagimet Biosciences Inc. Series A Stock

Search interest for Sagimet Biosciences Inc. Series A Stock has decreased by -78% in the last 30 days, reflecting a downward trend in search activity.

Time period: May 23, 2026 to June 22, 2026

Change:-78% versus previous 30 day period

Sagimet Biosciences Inc. Series A Quarterly Profit & Loss

All numbers in Millions USD

	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
Total Revenue	-	-	-	-	-	-	-	-	-	-
Gross Profit	-	-	-	-	-	-	-	-	-	-
Operating Income	-9	-8	-10	-16	-18	-19	-11	-14	-10	-11
EBITDA	1	2	-8	-14	-16	-18	-10	-12	-12	-10
Interest Expense	-	-	-	-	-	-	-	-	-	-
Depreciation	-	-	-	-	-	-	-	-	-	-
Income Before Tax	-8	-6	-8	-14	-16	-18	-10	-12	-9	-10
Income Tax Expense	-1	-8	-10	-	-	-	-	-	-	-
Net Income	-8	-6	-8	-14	-16	-18	-10	-12	-9	-10
Net Profit Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Sagimet Biosciences Inc. Series A Annual Profit & Loss

All numbers in Millions USD

	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Total Revenue	-	-	-	-	2	-	-
Gross Profit	0	0	0	0	2	-	-
Operating Income	-14	-11	-23	-31	-30	-54	-56
EBITDA	-14	-11	-23	-31	-27	-45	-51
Interest Expense	0	-	-	-	-	-	-
Depreciation	0	-	-	-	-	-	-
Income Before Tax	-14	-11	-24	-30	-27	-45	-51
Income Tax Expense	0	0	-23	-31	-2	-	-
Net Income	-14	-11	-24	-30	-27	-45	-51
Net Profit Margin	0.00%	0.00%	0.00%	0.00%	-1393.80%	0.00%	0.00%

Sagimet Biosciences Inc. Series A Quarterly Cash Flow

All numbers in Millions USD

	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
Net Income	-6	-8	-14	-16	-18	-10	-12	-9	-10
Operating Cash Flow	-6	-5	-19	-11	-14	-9	-10	-11	-8
Investing Cash Flow	3	-75	0	9	3	-13	0	14	10
Financing Cash Flow	104	0	-	-	-	0	0	-	-
Change in Cash	101	-80	-18	-1	-11	-22	-9	2	1

Sagimet Biosciences Inc. Series A Annual Cash Flow

All numbers in Millions USD

	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Net Income	-11	-24	-30	-27	-45	-51
Operating Cash Flow	-10	-21	-24	-23	-42	-45
Investing Cash Flow	0	-	-32	12	-61	4
Financing Cash Flow	68	9	0	86	104	0
Change in Cash	58	-11	-56	74	0	-40

Global Institutional Holdings in Sagimet Biosciences Inc. Series A

Funds	Holdings
Point72 Asset Management, L.P.	0.3%
Qube Research & Technologies	0.3%
Vanguard Group Inc	2.04%
Affinity Asset Advisors, LLC	1.41%
Blue Owl Capital Holdings LP	0.54%

See all

Insights on Sagimet Biosciences Inc. Series A

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

POSITIVE IMPACT
Price Rise
In the last 3 months, SGMT stock has moved up by 38.6%
NO EFFECT
Against Peers
In the last 1 year, Regeneron Pharmaceuticals, Inc. Common Stock has given 19.7% return, outperforming this stock by 43.1%

About Sagimet Biosciences Inc. Series A

Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic and fibrotic pathways in the United States. The company's lead drug candidate is Denifanstat, an oral, once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction-associated steatohepatitis, acne, and select forms of cancer. It also develops TVB-3567, a FASN inhibitor for the treatment of acne indication; and other oncology programs, such as solid tumor and glioblastoma. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.

Organisation	Sagimet Biosciences Inc. Series A
Headquarters	155 Bovet Road, San Mateo, CA, United States, 94402
Industry	Biotechnology
CEO	Mr. David A. Happel
E-voting on shares	Click here to vote

Key Management of Sagimet Biosciences Inc. Series A

Name	Title
Mr. David A. Happel	CEO, President & Director
Ms. Elizabeth Rozek Esq., J.D.	Chief Legal & Administrative Officer
Mr. Urs Greber Ph.D.	Co-Founder
Dr. Lucas Pelkmans Ph.D.	Co-Founder
Mr. Thierry Chauche	CFO & Principal Accounting Officer
Dr. Marie O'Farrell Ph.D.	Chief Scientific Officer
Mr. Robert D'Urso	Senior Vice President of New Products
Dr. Andreas Grauer M.D.	Chief Medical Officer

FAQs

What is Sagimet Biosciences Inc. Series A share price today?

Sagimet Biosciences Inc. Series A share price today is $6.68 as on June 19, 2026 at 8:46 am IST at the close of the market. Sagimet Biosciences Inc. Series A share today touched a day high of $6.86 and a low of $6.58.

What is the 52 week high and 52 week low for Sagimet Biosciences Inc. Series A share?

Sagimet Biosciences Inc. Series A share touched a 52 week high of $11.41 on July 25, 2025 and a 52 week low of $4.5 on March 30, 2026. Sagimet Biosciences Inc. Series A stock price today i.e. June 19, 2026 at 8:46 am IST is closed at $6.68,which is 41.45% down from its 52 week high and 48.44% up from its 52 week low.

What is Sagimet Biosciences Inc. Series A's market capitalisation today?

Sagimet Biosciences Inc. Series A market capitalisation is $0.00T as on June 19, 2026 at 8:46 am IST.

How to invest in Sagimet Biosciences Inc. Series A Stock (SGMT) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for Sagimet Biosciences Inc. Series A on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Sagimet Biosciences Inc. Series A Shares that will get you 0.2246 shares as per Sagimet Biosciences Inc. Series A share price of $6.68 per share as on June 19, 2026 at 8:46 am IST.

What is the minimum amount required to buy Sagimet Biosciences Inc. Series A Stock (SGMT) from India?

Indian investors can start investing in Sagimet Biosciences Inc. Series A (SGMT) shares with as little as ₹94.31 or $1 (as of June 22, 2026 at 5:40 am IST) using the INDmoney app.
For example: If you want to invest $10 or ₹943.10 in Sagimet Biosciences Inc. Series A stock (as per the Rupee-Dollar exchange rate as on June 22, 2026 at 5:40 am IST). Based on Sagimet Biosciences Inc. Series A share’s latest price of $6.68 as on June 19, 2026 at 8:46 am IST, you will get 1.4970 shares of Sagimet Biosciences Inc. Series A. Learn more about fractional shares .